Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Nuvation Bio Inc.

    NYSE: NUVB · Real-Time Price · USD
    2.01
    0.04 (2.03%)
    At close: Jun 23, 2025, 3:59 PM
    2.03
    1.00%
    After-hours: Jun 23, 2025, 07:59 PM EDT
    2.03%
    Bid 2.02
    Market Cap 681.92M
    Revenue (ttm) 10.96M
    Net Income (ttm) -606.38M
    EPS (ttm) -2.2
    PE Ratio (ttm) -0.91
    Forward PE -3.15
    Analyst Buy
    Ask 2.07
    Volume 7,567,174
    Avg. Volume (20D) 4,759,424
    Open 2.00
    Previous Close 1.97
    Day's Range 1.91 - 2.02
    52-Week Range 1.54 - 3.97
    Beta 1.37

    About NUVB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NUVB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Nuvation Bio Inc. is scheduled to release its earnings on Aug 4, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    5 months ago
    +14.44%
    Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription
    10 months ago
    -5.36%
    Nuvation Bio shares are trading lower. The company reported Q2 financial results.
    news image

    1 week ago · reuters.com

    US FDA approves Nuvation Bio's lung cancer therapy

    The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

    news image

    1 week ago · businesswire.com

    U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Dru...

    news image

    1 week ago · https://www.defenseworld.net

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in i...

    news image

    1 month ago · businesswire.com

    Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results fr...

    news image

    1 month ago · businesswire.com

    Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a match...

    news image

    1 month ago · seekingalpha.com

    Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

    Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sj...

    news image

    1 month ago · zacks.com

    Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates

    Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes

    Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of...

    news image

    1 month ago · businesswire.com

    Nuvation Bio to Present at The Citizens Life Sciences Conference

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financia...

    news image

    2 months ago · businesswire.com

    Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

    NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter...

    Add to Watchlist